A medical device can be implanted in a body to perform one or more tasks including monitoring, detecting, or sensing physiological information in or otherwise associated with the body, diagnosing a physiological condition or disease, treating or providing a therapy for a physiological condition or disease, or restoring or otherwise altering the function of an organ or a tissue. Examples of an implantable medical device can include a cardiac rhythm management device, such as a pacemaker, a cardiac resynchronization therapy device, a cardioverter or defibrillator, a neurological stimulator, a neuromuscular stimulator, or a drug delivery system.
In various examples, cardiac rhythm or function management devices can sense intrinsic heart contractions, deliver pacing pulses to evoke responsive heart contractions, or deliver a shock to interrupt certain arrhythmias. In certain examples, one or more of these functions can help improve a patient's heart rhythm or can help coordinate a spatial nature of a heart contraction, either of which can improve cardiac output of blood to help meet the patient's metabolic need for such cardiac output.
This document discusses, among other things, a system and method for generating a stimulation energy to provide His-bundle stimulation for a cardiac cycle, receiving electrical information from the heart over at least a portion of the cardiac cycle, determining a characteristic of at least a portion of the received electrical information for the cardiac cycle, and classifying the cardiac cycle using the determined characteristic.
In Example 1, a system includes a cardiac stimulation circuit configured to generate a stimulation energy to provide His-bundle stimulation for a cardiac cycle, a cardiac sensing circuit configured to receive electrical information from the heart over at least a portion of the cardiac cycle, and a processor configured to determine a characteristic of the received electrical information from the heart over at least a portion of the cardiac cycle using the received electrical information, wherein the processor is configured to classify the cardiac cycle using the determined characteristic.
In Example 2, the characteristic of the received electrical information of Example 1 optionally includes at least one of:
(1) a width of a QRS complex;
(2) an amplitude of the QRS complex;
(3) a slope of the QRS complex;
(4) a latency of the QRS complex;
(5) a correlation of the received electrical information to at least one of a myocardium capture template or a His-bundle capture template;
(6) a measure of a heart hemodynamic condition;
(7) a vector of the QRS complex; or
(8) a morphology of the QRS complex.
In Example 3, the processor of any one or more of Examples 1-2 is optionally configured to classify the cardiac cycle, using the determined characteristic, as at least one of:
(1) myocardium capture;
(2) His-bundle capture;
(3) partial His-bundle capture;
(4) AV node capture;
(5) non-capture; or
(6) fusion of at least one of myocardium capture, His-bundle capture, partial His-bundle capture, AV node capture, or non-capture.
In Example 4, the processor of one or more of Examples 1-3 is optionally configured to provide the classification to an external module, wherein the external module is configured to display a classification trend.
In Example 5, the processor of one or more of Examples 1-4 is optionally configured to classify a plurality of cardiac cycles, wherein the classification includes His-bundle capture, and wherein the classification trend includes a His-bundle capture trend.
In Example 6, the processor of one or more of Examples 1-5 is optionally configured to determine a His-bundle capture threshold using the determined characteristic.
In Example 7, the processor of one or more of Examples 1-6 is optionally configured to compare the determined characteristic with a corresponding characteristic from at least one of a myocardium capture template or a His-bundle capture template, and to determine a His-bundle capture threshold using the comparison.
In Example 8, the processor of one or more of Examples 1-7 is optionally configured to determine a first His-bundle capture threshold for a first pacing waveform and a second His-bundle capture threshold for a second pacing waveform, the second pacing waveform different than the first pacing waveform.
In Example 9, the processor of any one or more of Examples 1-8 is optionally configured to determine a first His-bundle capture threshold for a first pacing configuration and a second His-bundle capture threshold for a second pacing configuration, the second pacing configuration different than the first pacing configuration.
In Example 10, the processor of one or more of Examples 1-9 is optionally configured to recommend one of the first or second pacing configurations based on at least one of:
(1) a preferred pacing configuration;
(2) a pacing threshold; or
(3) a His-bundle capture quality.
In Example 11, a method includes generating a stimulation energy to provide His-bundle stimulation for a cardiac cycle, receiving electrical information from the heart over at least a portion of the cardiac cycle, determining a characteristic of at least a portion of the received electrical information for the cardiac cycle, and classifying the cardiac cycle using the determined characteristic.
In Example 12, the determining the characteristic of at least a portion of the received electrical information of one or more of Examples 1-11 includes determining at least one of:
(1) a width of an QRS complex;
(2) an amplitude of the QRS complex;
(3) a slope of the QRS complex;
(4) a latency of the QRS complex;
(5) a correlation of the received electrical information to at least one of a myocardium capture template or a His-bundle capture template;
(6) a measure of a heart hemodynamic condition;
(7) a vector of the QRS complex; or
(8) a morphology of the QRS complex.
In Example 13, the classifying the cardiac cycle of one or more of Examples 1-12 includes classifying the cardiac cycle as at least one of:
(1) myocardium capture;
(2) His-bundle capture;
(3) partial His-bundle capture;
(4) AV node capture;
(5) non-capture; or
(6) fusion of at least one of myocardium capture, His-bundle capture, partial His-bundle capture, AV node capture, or non-capture.
In Example 14, any one or more of Examples 1-13 optionally includes providing classification information to an external module, and displaying a classification trend.
In Example 15, the classifying the cardiac cycle of any one or more of Examples 1-14 optionally includes classifying a plurality of cardiac cycles into one or more class, wherein the class includes His-bundle capture, and wherein the classification trend includes a His-bundle capture trend.
In Example 16, any one or more of Examples 1-15 optionally includes determining a His-bundle capture threshold using the determined characteristic.
In Example 17, any one or more of Examples 1-16 optionally includes comparing the determined characteristic with a corresponding characteristic from at least one of a myocardium capture template or a His-bundle capture template, and determining a His-bundle capture threshold using the comparison.
In Example 18, any one or more of Examples 1-17 optionally includes determining a first His-bundle capture threshold for a first pacing waveform and a second His-bundle capture threshold for a second pacing waveform, the second pacing waveform different than the first pacing waveform.
In Example 19, any one or more of Examples 1-18 optionally includes determining a first His-bundle capture threshold for a first pacing configuration and a second His-bundle capture threshold for a second pacing configuration, the second pacing configuration different than the first pacing configuration.
In Example 20, any one or more of Examples 1-19 optionally includes recommending one of the first or second pacing configurations based on at least one of:
(1) a preferred pacing configuration;
(2) a pacing threshold; or
(3) a His-bundle capture quality.
This overview is intended to provide an overview of subject matter of the present patent application. It is not intended to provide an exclusive or exhaustive explanation of the invention. The detailed description is included to provide further information about the present patent application.
In the drawings, which are not necessarily drawn to scale, like numerals may describe similar components in different views. Like numerals having different letter suffixes may represent different instances of similar components. The drawings illustrate generally, by way of example, but not by way of limitation, various embodiments discussed in the present document.
The natural conduction pathway of the heart originates in the sinoatrial (SA) node in the right atrium of the heart. When functioning properly, the SA node is the primary natural pacemaker of the heart, generating intrinsic electrical impulses or action potentials, triggering the atria to contract. From the SA node, the conduction pathway follows internodal pathways to the atrioventricular (AV) node, located between the atrium and the ventricle. Following a delay at the AV node, conduction continues through the His-bundle to the left and right bundle branches, then to the purkinje fibers, to the apex of the heart, and finally up and around to the ventricular myocardium.
Cardiac contractions utilizing the natural conduction pathway, such as intrinsic contractions, are generally advantageous over typical apical or biventricular pacing, providing a faster, more focused and efficient contraction. Accordingly, providing stimulation energy (e.g., a pacing energy) to a portion of the natural conduction pathway (e.g., the His-bundle, etc.) can utilize the faster conducting fibers (in contrast to slower activating muscle cells), providing more physiological stimulation and better hemodynamic benefits.
Further, it is possible that the actual blockage in left bundle branch block (LBBB) can be located in the His-bundle. In these instances, cardiac resynchronization therapy with a single lead at the His-bundle (e.g., distal the blockage/defect) may be more effective than traditional biventricular pacing. However, His-bundle pacing, generally, has higher and unstable thresholds due to lead placement and difficulty in capturing the purkinje system.
Accordingly, the present inventors have recognized, among other things, a system and method for classifying a cardiac cycle (e.g., as partial or complete His-bundle capture, myocardium capture, AV-node capture, non-capture, etc.), for automatically determining a His-bundle threshold, for adjusting a pacing configuration, or for monitoring or reporting the stability of the His-bundle pacing.
(1) a His-bundle capture 101;
(2) a myocardium capture 102; and
(3) an intrinsic depolarization 103.
As seen in the example of
In an example, the cardiac sensing circuit 111 can be configured to receive electrical information from the heart, for example, over at least a portion of the cardiac cycle the stimulation energy was generated for, above. In an example, the electrical information can include an electrical cardiogram (ECG) signal (e.g., an evoked response, a subcutaneous ECG, an intracardiac electrogram, or other), or one or more other electrical signals indicative of cardiac information (e.g., heart sounds, intrathoracic impedance, pressure, etc.). For example, such electrical information can be sensed using the cardiac sensing circuit 111 via one or more electrodes located within or near the heart (e.g., an implantable lead electrode or an electrode on the housing of the IMD), or located externally to the subject (e.g., such as a surface ECG).
The processor 112 can be configured to determine a characteristic of the received electrical information from the heart over at least a portion of the cardiac cycle using the received electrical information. For example, the characteristic of the received electrical information can correlate to the onset of a ventricular contraction (e.g., a Q wave, a QRS complex, or the like). In an example, the characteristics can include at least one of:
(1) a width of a QRS complex;
(2) an amplitude of the QRS complex;
(3) a slope of the QRS complex;
(4) a latency of the QRS complex;
(5) a correlation of the received electrical information to at least one of a myocardium capture template or a His-bundle capture template;
(6) a measure of a heart hemodynamic condition;
(7) a vector of the QRS complex; or
(8) a morphology of the QRS complex.
In an example, one or more other characteristics can be used, such as measures of contractility, synchrony, cardiac output, etc., a QRS axis/polarity or repolarization index (e.g., T-wave polarity, measures or surrogate measures of repolarization time, etc.), etc.
Further, in an example, the processor 112 can be configured to classify the cardiac cycle using the determined characteristic (e.g., using a detected change in the determined characteristic, comparing the determined characteristic to a threshold, etc.). In an example, the cardiac cycle can be classified as at least one of:
(1) myocardium capture;
(2) His-bundle capture;
(3) partial His-bundle capture;
(4) AV node capture;
(5) non-capture; or
(6) fusion of at least one of myocardium capture, His-bundle capture, partial
His-bundle capture, or non-capture.
In other examples, one or more other classes can be used.
In an example, the processor 112 can be configured to report (or make available) one or more classifications or results from the classification to an external module (e.g., an external programmer, directly to a clinician's handheld mobile device, email, etc.). In an example, the processor 112 can be configured to classify a plurality of cardiac cycles, count or store one or more of the results from the classification, and, when the His-bundle capture percentage is below a threshold, the processor can be configured to do one or more of the following:
(1) provide an alert to an external module;
(2) reduce the stimulation energy to save power;
(3) increase the stimulation energy (e.g., the pacing threshold) to ensure His-bundle capture;
(4) switch to a different pacing configuration (e.g., different pacing waveform, site, etc.); or
(5) initiate a test to determine the His-bundle threshold.
In certain examples, the percentage of the His-bundle capture can be trended and the trending can be provided to an external module and displayed to the user.
In an example, the processor 112 can be configured to increase the stimulation energy (e.g., the pacing threshold) to increase the His-bundle capture percentage. In certain examples, the stimulation energy can be increased after a time interval (e.g., a number of hours, days, etc.), after a number of cardiac cycles, after a number of His-bundle captures, after a number of His-bundle non-captures, at a threshold His-bundle capture percentage, etc.
In an example, the processor 112 can be configured to determine a His-bundle capture threshold using one or more of the determined characteristics (e.g., QRS width, height, slope, etc.). For example, the His-bundle capture threshold can be used to create or update one or more of a myocardium capture template or a His-bundle capture template. In an example, the processor 112 can be configured to create or update one or more myocardium capture templates, or one or more His-bundle capture templates. Further, the processor 112 can be configured to compare the determined characteristic with a corresponding characteristic from at least one of a myocardium capture template or a His-bundle capture template, and to determine a His-bundle capture threshold or a myocardium capture threshold using the comparison. In certain examples, capture thresholds can be determined for a plurality of cardiac cycles, and a plurality of different pacing configurations, to determine an optimal suggested configuration. In certain examples, the optimum suggested configuration can be based on, among other things, a preferred pacing configuration, a pacing output or pacing output energy, a His-bundle capture quality (e.g., tallied over a plurality of cardiac cycles, including, for example, percentage of His-bundle captures, etc.).
Further, in certain examples, one or more templates (e.g., an individual template, or one or more of a group of templates) can be used to distinguish between partial and complete His-bundle capture. In certain examples, one or more defects in the natural conduction pathway (e.g., left or right bundle branch block, infarct, etc.) can inhibit a complete His-bundle capture, instead allowing only a partial His-bundle capture. In a partial His-bundle capture, a portion of the heart can utilize the faster conduction pathways of the purkinje fibers, etc., to quickly and efficiently depolarize, while another portion must rely on slower, less efficient cell-to-cell depolarization of the cardiac muscle, if any depolarization at all. In an example, one or more methods can be used to distinguish between complete and partial His-bundle capture, including:
(1) using multiple electrograms from different electrodes (e.g., to receive different local information regarding the shape and direction of the depolarization);
(2) using multi-channel subcutaneous or intracardiac ECG signals;
(3) using surface ECG axis changes (e.g., during device follow-up, or when surface ECG is available; or
(4) using clinician triggered templates, or previously stored templates of different partial or complete His-bundle capture waveforms, etc.
In an example, the clinician triggered templates, or previously stored templates can include an individually generated template (e.g., a template obtained from the subject 101 such as using the technique of
In an example, the IMD 105 can include a pacemaker, a defibrillator, or one or more other implantable medical devices. In an example, the IMD 105 can include an antenna configured to provide radio-frequency or other communication between the IMD 105 and the external module 115 (or other external device).
In an example, the external module 115 can include an external antenna (e.g., or one or more external antennae). In an example, the external module 115 can include a local medical device programmer or other local external module (e.g., a medical device programmer or other external module within wireless communication of the IMD 105 antenna). In other examples, the external module 115 can include a remote medical device programmer or one or more other remote external modules (e.g., outside of wireless communication range of the IMD 105 antenna, but coupled to the IMD 105 using a local external device, such as a repeater). In an example, the external module 115 can be configured to send information to or receive information from the IMD 105. The information can include medical device programming information, subject data, device data, or other instructions, alerts, or other information. In an example, the external module 115 can be configured to display information (e.g., received information) to a user. Further, the local programmer or the remote programmer can be configured to communicate the sent or received information to a user or physician, such as by sending an alert via email of the status of the subject 101 or the system components.
The atrial sensing channel 60 can include at least one of a right atrial sensing channel or a left atrial sensing channel. In other examples, the IMD 105 can include a combination of at least one of the a right ventricular sensing channel 10, the right ventricular pacing channel 20, the left ventricular sensing channel 30, the left ventricular pacing channel 40, or the atrial sensing channel 60.
In certain examples, the right ventricular sensing channel 10 can include a sense amplifier 11, the left ventricular sensing channel 30 can include a sense amplifier 31, the right ventricle pacing channel 20 can include a pulse generator 21, the left ventricular pacing channel 40 can include a pulse generator 41, and the atrial sensing channel 60 can include a sense amplifier 61. In other examples, the right ventricular sensing channel 10 or the right ventricular pacing channel 20 can be coupled to an electrode 16 disposed on a lead 15 or elsewhere, the left ventricular sensing channel 30 or the left ventricular pacing channels 40 can be coupled to an electrode 36 disposed on a lead 35 or elsewhere, or the atrial sensing channel 60 can be coupled to an electrode 66 disposed on a lead 65 or elsewhere.
In certain examples, the lead 15 can be configured to electrically couple the sense amplifier 11 or the pulse generator 21 to the electrode 16, which can be configured to be located in a right ventricle, such as in the septal region, the right ventricular outflow tract, the free wall region, or another region of the right ventricle. Similarly, the lead 35 can be configured to electrically couple the sense amplifier 31 or the pulse generator 41 to the electrode 36, which can be configured to be located in, on, or near a left ventricle, such as in the septal region, the free wall region, or another region of the left ventricle or in the coronary vasculature. Further, the lead 65 can be configured to electrically couple the sense amplifier 61 to the electrode 66, which can be configured to be located in at least one of a right atrium or a left atrium of the subject 101.
In certain examples, the IMD 105 can include one or more other pacing or sensing channels, such as an atrial pacing channel, an internal thoracic pacing or sensing channel configured to couple the processor 112 to an internal thoracic location external to the heart (e.g., through one or more leads, electrodes, pulse generators, or sense amplifiers), one or more other atrial or ventricular pacing or sensing channels, etc. In an example, the internal thoracic pacing or sensing channel can be configured to send or receive information to or from a housing “can” electrode, located on the exterior housing of an implantable medical device located in the internal thoracic location external to the heart. In other examples, the IMD 105 can include one or more other right or left ventricular sensing or pacing channels, such as a right ventricular apex backup pacing channel, should His-bundle pacing become unreliable or the threshold increase beyond a safe level.
In the example of
Similar to the example illustrated in
The right ventricular apex lead 15 can include a first electrode 16A configured to be located in the superior vena cava of a heart 102, and a second electrode 16B, a third electrode 16B, and a fourth electrode 16D configured to be located in the right ventricle 560 of the heart 102. In an example, one or more electrodes, such as the first electrode 16A or the second electrode 16B, can include a shocking coil electrode configured to deliver a high energy shock (e.g., 0.1 Joule or greater, etc.) to the heart. In certain examples, the first electrode 16A can include a proximal defibrillation coil electrode and the second electrode 16B can include a distal defibrillation coil electrode.
The left ventricular lead 35 can include a fifth electrode 36A and a sixth electrode 36B configured to be located in, on, or near the left ventricle 565 of the heart 102, such as within the coronary vasculature. In an example, the sixth electrode 36B can include a distal pacing or sensing electrode. The right ventricular septum lead 65 can include a seventh electrode 66A, an eighth electrode 66B, and a ninth electrode 66C configured to be located along the septum in the right ventricle 560 of the heart 102. In an example, the right ventricular septum lead 65 can be configured to provide His-bundle pacing along the septum wall. In certain examples, the housing can electrode 508 can be electrically coupled to at least one other electrode (e.g., the first electrode 16A), or the housing can electrode 508 can be electrically isolated from other electrodes and capable of independent control. Further, in certain examples, the first electrode 16A through the ninth electrode 66C can include at least one of a coil-type electrode, a ring-type electrode, or a tip electrode.
In certain examples, the right ventricular apex lead 15 can be configured to electrically couple the IMD 105 to at least one of the right ventricle 560, the right atrium 570, or the superior vena cava using at least one electrode (e.g., the first electrode 16A, the second electrode 16B, the third electrode 16C, or the fourth electrode 16D), the left ventricular lead 35 can be configured to electrically couple the IMD 105 to the left ventricle 565 using at least one electrode (e.g., the fifth electrode 36A or the sixth electrode 36B), or the right ventricular septum lead 65 can be configured to electrically couple the IMD 105 to the interventricular septum using at least one electrode (e.g., the seventh electrode 66A, the eighth electrode 66B, or the ninth electrode 66C). In an example, at least one of the second electrode 16B, the third electrode 16C, or the fourth electrode 16D, can be configured to be located in, on, or near a right apical region of the heart 102. In other examples, the fifth electrode 36A or the sixth electrode 36B can be configured to be located in, on, or near a left apical region of the heart 102 or a left ventricular free lateral wall of the heart 102.
In certain examples, a cardiac rhythm management device capable of delivering a defibrillation energy can include a shocking electrode, such as the first electrode 16A, electrically tied or coupled to the housing can electrode.
At 610, if no capture is detected, then, at 630, the pacing voltage is increased. In an example, a non-capture template can be established. Then, at each subsequent step-up test, the previous non-capture template can be supplemented, or replaced. At 605, the pacing step-up test is performed, including delivering the stimulation energy.
At 610, if capture is detected, and. at 615, initial capture is determined, then, at 620, the current pacing level is set as the myocardium capture threshold. At 625, a myocardium capture template is established.
In an example, the myocardium capture template can be established using the first initial capture. Then, at each subsequent step-up test, the previous myocardium capture template can be supplemented, or replaced. Various statistical techniques can be used to supplement a previous template (e.g., a moving average, etc.). In other examples, a clinical myocardium capture template can be used initially and supplemented or replaced. One or more of a group of myocardium capture templates can be used to determine myocardium capture or His-bundle capture (e.g., comparing one or more characteristics, correlating the current waveform to the template, etc.).
At 630, the pacing voltage is increased, and, at 605, the pacing step-up test is performed again, including delivering the stimulation energy.
At 615, if the detected capture is not the first capture since the initial pacing step-up test during this session, then, at 635, His-bundle capture is determined. At 635, several criteria can be investigated to determine if the detected capture is His-bundle capture. For example, the electrical information (e.g., a QRS waveform, etc.) from the heart can be correlated with an intrinsic capture, such as the subject's previously captured intrinsic waveform or a clinical intrinsic waveform. In other examples, the electrical information can be compared with the myocardium capture template, a physician triggered template, or a His-bundle capture template. In an example, His-bundle capture can be determined using one or more characteristics of the electrical information, such as:
(1) QRS width (e.g., a reduction of QRS width from myocardium capture, an increase pacing voltage coupled with a reduction of QRS width, comparison of intrinsic QRS width, etc.);
(2) QRS amplitude (e.g., a change in QRS amplitude, such as an increase in QRS amplitude over myocardium capture, comparison of intrinsic QRS amplitude, etc.);
(3) dV/dt (e.g., an increase in the slope of the QRS complex);
(4) QRS latency;
(5) Correlation to myocardium capture template;
(6) Normalization of the QRS axis vector; or
(7) Indication of synchronization using other hemodynamic sensors (e.g., heart sounds, blood pressure, respiration, etc.).
At 635, if His-bundle capture (e.g., partial His-bundle capture, or complete His-bundle capture) is not detected, then, at 630, the pacing voltage is increased, and, at 605, the pacing step-up test is performed again, including delivering the stimulation energy. At 635, if His-bundle capture is detected, then, at 640, the current pacing level is set as the His-bundle capture threshold.
At 645, one or more of a group of His-bundle capture templates can be established, such as to correlate to a degree of His-bundle capture (e.g., partial His-bundle capture, complete His-bundle capture, myocardium capture, non-capture etc.). In an example, the His-bundle capture template can be established using the first initial His-bundle capture. Then, at each subsequent step-up test, the previous His-bundle capture template can be supplemented, or replaced. In an example, the myocardium capture template, the non-capture template, the His-bundle capture templates established during the first initial His-bundle capture, or one or more of the subsequent step-up tests can be included in a group of His-bundle capture templates. The group of His-bundle capture templates can include two or more templates corresponding to various degrees of capture (e.g., non capture, one or more degrees of partial His-bundle capture, complete His-bundle capture, myocardium capture, AV-node capture, etc.). Various statistical techniques can be used to supplement a previous template (e.g., a moving average, etc.). In other examples, a clinical His-bundle capture template can be used initially and supplemented or replaced. The His-bundle capture templates can be used to determine His-bundle capture or myocardium capture (e.g., comparing one or more characteristics, correlating the current waveform to the template, etc.). At 650, the pacing step-up test is ended.
In certain examples, during the step-up test, pacing may directly capture the His-bundle without first capturing the myocardium. In this case, when it is determined that the pace has captured the heart, the His-bundle capture criteria will be directly evaluated no matter whether it is the initial capture or not.
At 710, if His-bundle capture is detected, then, at 715, the current pacing level is set as the His-bundle capture threshold. At 720, a His-bundle capture template is established. At 725, the pacing voltage is decreased, and, at 705, the step-down pacing test is performed.
At 710, if His-bundle capture is not detected, and, at 730, myocardium capture is detected, then, at 735, the current pacing level is set as the myocardium threshold. At 740, a myocardium capture template is established. At 745, the pacing voltage is decreased and at 705, the step-down pacing test is performed. At 730, if no myocardium capture is detected, then, at 750, the step-down pacing test is ended.
In other examples, a step-up threshold test can be performed. At each increase in pacing voltage, a determined characteristic can be compared to a corresponding characteristic or characteristic template. In an example, the capture (e.g., the His-bundle capture, the myocardium capture, etc.) can be detected, or the threshold (e.g., the His-bundle capture threshold, the myocardium capture threshold, etc.) can be determined, if the determined characteristic matches the corresponding characteristic (e.g., autocorrelation coefficient reaches a maximum, etc.).
In an example, the system or method disclosed herein can report His-bundle captured cardiac cycles, partial His-bundle captured cardiac cycles, myocardium captured cardiac cycles, non-captured cardiac cycles, etc. In an example, each cardiac cycle can be classified. If His-bundle capture falls below a percentage, a new His-bundle threshold test can be triggered and a pacing parameter can be adjusted. If a His-bundle capture percentage is below a threshold an alert can be issued to physicians and pacing output can be reduced to save energy. Further, in certain examples, this or other information can be trended and displayed (e.g., using the external module).
The above detailed description includes references to the accompanying drawings, which form a part of the detailed description. The drawings show, by way of illustration, specific embodiments in which the invention can be practiced. These embodiments are also referred to herein as “examples.” Such examples can include elements in addition to those shown and described. However, the present inventor also contemplates examples in which only those elements shown and described are provided.
All publications, patents, and patent documents referred to in this document are incorporated by reference herein in their entirety, as though individually incorporated by reference. In the event of inconsistent usages between this document and those documents so incorporated by reference, the usage in the incorporated reference(s) should be considered supplementary to that of this document; for irreconcilable inconsistencies, the usage in this document controls.
In this document, the terms “a” or “an” are used, as is common in patent documents, to include one or more than one, independent of any other instances or usages of “at least one” or “one or more.” In this document, the term “or” is used to refer to a nonexclusive or, such that “A or B” includes “A but not B,” “B but not A,” and “A and B,” unless otherwise indicated. In the appended claims, the terms “including” and “in which” are used as the plain-English equivalents of the respective terms “comprising” and “wherein.” Also, in the following claims, the terms “including” and “comprising” are open-ended, that is, a system, device, article, or process that includes elements in addition to those listed after such a term in a claim are still deemed to fall within the scope of that claim. Moreover, in the following claims, the terms “first,” “second,” and “third,” etc. are used merely as labels, and are not intended to impose numerical requirements on their objects.
The above description is intended to be, and not restrictive. For example, the above-described examples (or one or more aspects thereof) may be used in combination with each other. Other embodiments can be used, such as by one of ordinary skill in the art upon reviewing the above description. The Abstract is provided to comply with 37 C.F.R. §1.72(b), to allow the reader to quickly ascertain the nature of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims. Also, in the above Detailed Description, various features may be grouped together to streamline the disclosure. This should not be interpreted as intending that an unclaimed disclosed feature is essential to any claim. Rather, inventive subject matter may lie in less than all features of a particular disclosed embodiment. Thus, the following claims are hereby incorporated into the Detailed Description, with each claim standing on its own as a separate embodiment. The scope of the invention should be determined with reference to the appended claims, along with the full scope of equivalents to which such claims are entitled.
This application claims the benefit of priority under 35 U.S.C. §119(e) of Dong et al., U.S. Provisional Patent Application Ser. No 61/328,248, entitled “HIS-BUNDLE CAPTURE VERIFICATION AND MONITORING”, filed on Apr. 27, 2010, which is herein incorporated by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
3614955 | Mirowski | Oct 1971 | A |
3804098 | Friedman | Apr 1974 | A |
3866615 | Hewson | Feb 1975 | A |
3911928 | Lagergren | Oct 1975 | A |
3942536 | Mirowski et al. | Mar 1976 | A |
3949757 | Sabel | Apr 1976 | A |
3995623 | Blake et al. | Dec 1976 | A |
4026303 | Babotai | May 1977 | A |
4030508 | Thalen | Jun 1977 | A |
4057067 | Lajos | Nov 1977 | A |
4106512 | Bisping | Aug 1978 | A |
4136703 | Wittkampf | Jan 1979 | A |
4154247 | O'Neill | May 1979 | A |
4217913 | Dutcher | Aug 1980 | A |
4258725 | O'Neill | Mar 1981 | A |
4278093 | Lafortune et al. | Jul 1981 | A |
4282885 | Bisping | Aug 1981 | A |
4289134 | Bernstein | Sep 1981 | A |
4289144 | Gilman | Sep 1981 | A |
4311153 | Smits | Jan 1982 | A |
4332259 | McCorkle, Jr. | Jun 1982 | A |
4365639 | Goldreyer | Dec 1982 | A |
4393883 | Smyth et al. | Jul 1983 | A |
4402329 | Williams | Sep 1983 | A |
4437474 | Peers-Trevarton | Mar 1984 | A |
4458677 | McCorkle, Jr. | Jul 1984 | A |
4458695 | Peers-Trevarton | Jul 1984 | A |
4463765 | Gold | Aug 1984 | A |
4469104 | Peers-Trevarton | Sep 1984 | A |
4497326 | Curry | Feb 1985 | A |
4540236 | Peers-Trevarton | Sep 1985 | A |
4543956 | Herscovici | Oct 1985 | A |
4549548 | Wittkampf et al. | Oct 1985 | A |
4559951 | Dahl et al. | Dec 1985 | A |
4567901 | Harris | Feb 1986 | A |
4570642 | Kane et al. | Feb 1986 | A |
4577643 | Beranek | Mar 1986 | A |
4589420 | Adams et al. | May 1986 | A |
4602645 | Barrington et al. | Jul 1986 | A |
4603705 | Speicher et al. | Aug 1986 | A |
4624265 | Grassi | Nov 1986 | A |
4624266 | Kane | Nov 1986 | A |
4627439 | Harris | Dec 1986 | A |
4630204 | Mortara | Dec 1986 | A |
4633880 | Osypka et al. | Jan 1987 | A |
4641649 | Walinsky et al. | Feb 1987 | A |
4643201 | Stokes | Feb 1987 | A |
4646755 | Kane | Mar 1987 | A |
4649937 | DeHaan et al. | Mar 1987 | A |
4649938 | McArthur | Mar 1987 | A |
4664113 | Frisbie et al. | May 1987 | A |
4667686 | Peers-Travarton | May 1987 | A |
H356 | Stokes et al. | Nov 1987 | H |
4721115 | Owens | Jan 1988 | A |
4751931 | Briller et al. | Jun 1988 | A |
4784161 | Skalsky et al. | Nov 1988 | A |
4785815 | Cohen | Nov 1988 | A |
4799486 | DuFault | Jan 1989 | A |
4799493 | DuFault | Jan 1989 | A |
4819647 | Byers et al. | Apr 1989 | A |
4819661 | Heil, Jr. et al. | Apr 1989 | A |
4819662 | Heil, Jr. et al. | Apr 1989 | A |
4876109 | Mayer et al. | Oct 1989 | A |
4886074 | Bisping | Dec 1989 | A |
4892102 | Astrinsky | Jan 1990 | A |
4895152 | Callaghan et al. | Jan 1990 | A |
4922607 | Doan et al. | May 1990 | A |
4922927 | Fine et al. | May 1990 | A |
4924881 | Brewer | May 1990 | A |
4953564 | Berthelsen | Sep 1990 | A |
4967766 | Bradshaw | Nov 1990 | A |
4972848 | Di Domenico et al. | Nov 1990 | A |
4994078 | Jarvik | Feb 1991 | A |
5002067 | Berthelsen et al. | Mar 1991 | A |
5007864 | Stutz, Jr. | Apr 1991 | A |
5016646 | Gotthardt et al. | May 1991 | A |
5050601 | Kupersmith et al. | Sep 1991 | A |
5056516 | Spehr | Oct 1991 | A |
5063932 | Dahl et al. | Nov 1991 | A |
5076285 | Hess et al. | Dec 1991 | A |
5083564 | Scherlag | Jan 1992 | A |
5092879 | Jarvik | Mar 1992 | A |
5129404 | Spehr et al. | Jul 1992 | A |
5144960 | Mehra et al. | Sep 1992 | A |
5152299 | Soukup | Oct 1992 | A |
5174289 | Cohen | Dec 1992 | A |
5179962 | Dutcher et al. | Jan 1993 | A |
5181511 | Nickolls et al. | Jan 1993 | A |
5223226 | Wittmer et al. | Jun 1993 | A |
5242430 | Arenas et al. | Sep 1993 | A |
5255693 | Dutcher et al. | Oct 1993 | A |
5259394 | Bens | Nov 1993 | A |
5259395 | Li | Nov 1993 | A |
5267560 | Cohen | Dec 1993 | A |
5275620 | Darby et al. | Jan 1994 | A |
5282845 | Bush et al. | Feb 1994 | A |
5299569 | Wernicke et al. | Apr 1994 | A |
5300108 | Rebell et al. | Apr 1994 | A |
5304219 | Chernoff et al. | Apr 1994 | A |
5306292 | Lindegren | Apr 1994 | A |
5313953 | Yomtov et al. | May 1994 | A |
5320642 | Scherlag | Jun 1994 | A |
5324327 | Cohen | Jun 1994 | A |
5336252 | Cohen | Aug 1994 | A |
5342414 | Mehra | Aug 1994 | A |
5344439 | Otten | Sep 1994 | A |
5358516 | Myers et al. | Oct 1994 | A |
5366496 | Dahl et al. | Nov 1994 | A |
5370665 | Hudrlik | Dec 1994 | A |
5374286 | Morris | Dec 1994 | A |
5381790 | Kanesaka | Jan 1995 | A |
5393929 | Yagihashi | Feb 1995 | A |
5405373 | Petersson et al. | Apr 1995 | A |
5411544 | Mar et al. | May 1995 | A |
5425755 | Doan | Jun 1995 | A |
5433735 | Zanakis et al. | Jul 1995 | A |
5439391 | McEtchin et al. | Aug 1995 | A |
5447533 | Vachon et al. | Sep 1995 | A |
5447534 | Jammet | Sep 1995 | A |
5456706 | Pless et al. | Oct 1995 | A |
5456708 | Doan et al. | Oct 1995 | A |
5466253 | Doan | Nov 1995 | A |
5476497 | Mower et al. | Dec 1995 | A |
5476499 | Hirschberg | Dec 1995 | A |
5476501 | Stewart et al. | Dec 1995 | A |
5476502 | Rubin | Dec 1995 | A |
5492119 | Abrams | Feb 1996 | A |
5500008 | Fain | Mar 1996 | A |
5514172 | Mueller | May 1996 | A |
5515848 | Corbett, III et al. | May 1996 | A |
5522874 | Gates | Jun 1996 | A |
5524338 | Martyniuk et al. | Jun 1996 | A |
5527344 | Arzbaecher et al. | Jun 1996 | A |
5531780 | Vachon | Jul 1996 | A |
5545201 | Helland et al. | Aug 1996 | A |
5554178 | Dahl et al. | Sep 1996 | A |
5571163 | Helland | Nov 1996 | A |
5578068 | Laske et al. | Nov 1996 | A |
5593405 | Osypka | Jan 1997 | A |
5593433 | Spehr et al. | Jan 1997 | A |
5609158 | Chan | Mar 1997 | A |
5628778 | Kruse et al. | May 1997 | A |
5628779 | Bornzin et al. | May 1997 | A |
5634829 | Kerul | Jun 1997 | A |
5634899 | Shapland et al. | Jun 1997 | A |
5674272 | Bush et al. | Oct 1997 | A |
5674274 | Morgan et al. | Oct 1997 | A |
5681013 | Rudolph | Oct 1997 | A |
5683447 | Bush et al. | Nov 1997 | A |
5702427 | Ecker et al. | Dec 1997 | A |
5709753 | Olson et al. | Jan 1998 | A |
5716390 | Li | Feb 1998 | A |
5718720 | Prutchi et al. | Feb 1998 | A |
5720099 | Parker et al. | Feb 1998 | A |
5728140 | Salo et al. | Mar 1998 | A |
5733323 | Buck et al. | Mar 1998 | A |
5755766 | Chastain et al. | May 1998 | A |
5769881 | Schroeppel et al. | Jun 1998 | A |
5772693 | Brownlee | Jun 1998 | A |
5782898 | Dahl et al. | Jul 1998 | A |
5800464 | Kieval | Sep 1998 | A |
5800465 | Thompson et al. | Sep 1998 | A |
5807306 | Shapland et al. | Sep 1998 | A |
5810887 | Accorti, Jr. et al. | Sep 1998 | A |
5814077 | Sholder et al. | Sep 1998 | A |
5814079 | Kieval | Sep 1998 | A |
5851227 | Spehr | Dec 1998 | A |
5871506 | Mower | Feb 1999 | A |
5871529 | Bartig et al. | Feb 1999 | A |
5871531 | Struble | Feb 1999 | A |
5876399 | Chia et al. | Mar 1999 | A |
5876431 | Spehr et al. | Mar 1999 | A |
5916214 | Cosio et al. | Jun 1999 | A |
5925045 | Reimels et al. | Jul 1999 | A |
5935159 | Cross, Jr. et al. | Aug 1999 | A |
5941868 | Kaplan | Aug 1999 | A |
5944710 | Dev et al. | Aug 1999 | A |
5964795 | McVenes et al. | Oct 1999 | A |
5972416 | Reimels et al. | Oct 1999 | A |
5995871 | Knisley | Nov 1999 | A |
6006139 | Kruse et al. | Dec 1999 | A |
6007476 | Wascher et al. | Dec 1999 | A |
6024739 | Ponzi et al. | Feb 2000 | A |
6059726 | Lee et al. | May 2000 | A |
6070104 | Hine et al. | May 2000 | A |
6086582 | Altman et al. | Jul 2000 | A |
6096069 | Bischoff | Aug 2000 | A |
6123084 | Jandak et al. | Sep 2000 | A |
6141588 | Cox et al. | Oct 2000 | A |
6141594 | Flynn et al. | Oct 2000 | A |
6161029 | Spreigl et al. | Dec 2000 | A |
6165164 | Hill et al. | Dec 2000 | A |
6212434 | Scheiner et al. | Apr 2001 | B1 |
6219581 | Schaldach et al. | Apr 2001 | B1 |
6230061 | Hartung | May 2001 | B1 |
6236887 | Ben-Haim et al. | May 2001 | B1 |
6254573 | Haim et al. | Jul 2001 | B1 |
6256541 | Heil et al. | Jul 2001 | B1 |
6267778 | Cohen | Jul 2001 | B1 |
6309370 | Haim et al. | Oct 2001 | B1 |
6341235 | Mower | Jan 2002 | B1 |
6345204 | Scheiner et al. | Feb 2002 | B1 |
6358247 | Altman et al. | Mar 2002 | B1 |
6363286 | Zhu et al. | Mar 2002 | B1 |
6416510 | Altman et al. | Jul 2002 | B1 |
6430441 | Levine | Aug 2002 | B1 |
6463334 | Flynn et al. | Oct 2002 | B1 |
6468263 | Fischell et al. | Oct 2002 | B1 |
6471697 | Lesh | Oct 2002 | B1 |
6484057 | Ideker et al. | Nov 2002 | B2 |
6505082 | Peterfeso et al. | Jan 2003 | B1 |
6535766 | Thompson et al. | Mar 2003 | B1 |
6540725 | Ponzi | Apr 2003 | B1 |
6542775 | Ding et al. | Apr 2003 | B2 |
6544270 | Zhang | Apr 2003 | B1 |
6547787 | Altman et al. | Apr 2003 | B1 |
6556874 | Audoglio | Apr 2003 | B2 |
6560489 | Hauck | May 2003 | B2 |
6575931 | Ponzi | Jun 2003 | B1 |
6585716 | Altman | Jul 2003 | B2 |
6606517 | Park et al. | Aug 2003 | B1 |
6609027 | Kroll et al. | Aug 2003 | B2 |
6623473 | Ponzi | Sep 2003 | B1 |
6623474 | Ponzi | Sep 2003 | B1 |
6643546 | Mathis et al. | Nov 2003 | B2 |
6650940 | Zhu et al. | Nov 2003 | B1 |
6702744 | Mandrusov et al. | Mar 2004 | B2 |
6702777 | Haim et al. | Mar 2004 | B2 |
6718206 | Casavant | Apr 2004 | B2 |
6766190 | Ferek-Petric | Jul 2004 | B2 |
6768923 | Ding et al. | Jul 2004 | B2 |
6801807 | Abrahamson | Oct 2004 | B2 |
6804555 | Warkentin | Oct 2004 | B2 |
6810286 | Donovan et al. | Oct 2004 | B2 |
6855124 | Gonzalez et al. | Feb 2005 | B1 |
6901289 | Dahl et al. | May 2005 | B2 |
6905476 | Ponzi | Jun 2005 | B2 |
6907285 | Denker et al. | Jun 2005 | B2 |
6909920 | Lokhoff et al. | Jun 2005 | B2 |
6915169 | Flynn et al. | Jul 2005 | B2 |
6931286 | Sigg et al. | Aug 2005 | B2 |
6937897 | Min et al. | Aug 2005 | B2 |
7027876 | Casavant et al. | Apr 2006 | B2 |
7039462 | Pastore et al. | May 2006 | B2 |
7096051 | Alder | Aug 2006 | B1 |
7113825 | Pastore et al. | Sep 2006 | B2 |
7130682 | Stahmann et al. | Oct 2006 | B2 |
7187970 | Shemer et al. | Mar 2007 | B2 |
7245973 | Liu et al. | Jul 2007 | B2 |
7257443 | Pastore et al. | Aug 2007 | B2 |
7280872 | Mosesov et al. | Oct 2007 | B1 |
7317950 | Lee | Jan 2008 | B2 |
7319900 | Kim et al. | Jan 2008 | B2 |
7359837 | Drew | Apr 2008 | B2 |
7392095 | Flynn et al. | Jun 2008 | B2 |
7395042 | Alder | Jul 2008 | B2 |
7400931 | Mandrusov et al. | Jul 2008 | B2 |
7460914 | Mandrusov et al. | Dec 2008 | B2 |
7509170 | Zhang et al. | Mar 2009 | B2 |
7512440 | Ortega et al. | Mar 2009 | B2 |
7529584 | Laske et al. | May 2009 | B2 |
7792580 | Borowitz et al. | Sep 2010 | B2 |
7817784 | Wang et al. | Oct 2010 | B2 |
8005544 | Zhu et al. | Aug 2011 | B2 |
8010191 | Zhu et al. | Aug 2011 | B2 |
8010192 | Zhu et al. | Aug 2011 | B2 |
8014861 | Zhu et al. | Sep 2011 | B2 |
8050756 | Zhu et al. | Nov 2011 | B2 |
8078287 | Liu et al. | Dec 2011 | B2 |
8285376 | Ortega et al. | Oct 2012 | B2 |
8290586 | Zhu et al. | Oct 2012 | B2 |
8326423 | Zhu et al. | Dec 2012 | B2 |
8346358 | Ortega et al. | Jan 2013 | B2 |
8423139 | Zhu et al. | Apr 2013 | B2 |
8428715 | Ortega et al. | Apr 2013 | B2 |
20010031986 | Hauck | Oct 2001 | A1 |
20010044619 | Altman | Nov 2001 | A1 |
20020010492 | Donovan et al. | Jan 2002 | A1 |
20020016615 | Dev et al. | Feb 2002 | A1 |
20020022863 | Hauck | Feb 2002 | A1 |
20020026228 | Schauerte | Feb 2002 | A1 |
20020049478 | Ding et al. | Apr 2002 | A1 |
20020058981 | Zhu et al. | May 2002 | A1 |
20020099413 | Mower | Jul 2002 | A1 |
20020120318 | Kroll et al. | Aug 2002 | A1 |
20020169484 | Mathis et al. | Nov 2002 | A1 |
20020183720 | Hill et al. | Dec 2002 | A1 |
20020193836 | Schmidt | Dec 2002 | A1 |
20020198583 | Rock et al. | Dec 2002 | A1 |
20030009145 | Struijker-Boudier | Jan 2003 | A1 |
20030032938 | Altman | Feb 2003 | A1 |
20030069625 | Ley et al. | Apr 2003 | A1 |
20030078625 | Casavant | Apr 2003 | A1 |
20030083711 | Yonce et al. | May 2003 | A1 |
20030093104 | Bonner et al. | May 2003 | A1 |
20030105492 | Ding et al. | Jun 2003 | A1 |
20030105496 | Yu et al. | Jun 2003 | A1 |
20030109914 | Westlund et al. | Jun 2003 | A1 |
20030113303 | Schwartz | Jun 2003 | A1 |
20030125615 | Schwartz | Jul 2003 | A1 |
20030129750 | Schwartz | Jul 2003 | A1 |
20030163184 | Scheiner et al. | Aug 2003 | A1 |
20030171723 | Ponzi | Sep 2003 | A1 |
20030195470 | Ponzi | Oct 2003 | A1 |
20040006265 | Alhussiny | Jan 2004 | A1 |
20040064176 | Min et al. | Apr 2004 | A1 |
20040104782 | Ruffieux | Jun 2004 | A1 |
20040106958 | Mathis et al. | Jun 2004 | A1 |
20040122484 | Hatlestad et al. | Jun 2004 | A1 |
20040153127 | Gordon et al. | Aug 2004 | A1 |
20040186546 | Mandrusov et al. | Sep 2004 | A1 |
20040213770 | Seward et al. | Oct 2004 | A1 |
20040214182 | Sharma et al. | Oct 2004 | A1 |
20040215240 | Lovett et al. | Oct 2004 | A1 |
20040215249 | Corbucci | Oct 2004 | A1 |
20040215251 | Sharma et al. | Oct 2004 | A1 |
20040260374 | Zhang et al. | Dec 2004 | A1 |
20050049516 | Ideker | Mar 2005 | A1 |
20050075677 | Ganion et al. | Apr 2005 | A1 |
20050125041 | Min et al. | Jun 2005 | A1 |
20050136385 | Mann | Jun 2005 | A1 |
20050137671 | Liu et al. | Jun 2005 | A1 |
20050152516 | Wang et al. | Jul 2005 | A1 |
20050159725 | Tockman et al. | Jul 2005 | A1 |
20050203580 | Prentice et al. | Sep 2005 | A1 |
20050267557 | Flynn et al. | Dec 2005 | A1 |
20050277993 | Mower | Dec 2005 | A1 |
20060030810 | Mandrusov et al. | Feb 2006 | A1 |
20060064027 | Borowitz et al. | Mar 2006 | A1 |
20060104596 | Askins et al. | May 2006 | A1 |
20060116596 | Zhou et al. | Jun 2006 | A1 |
20060136001 | Ortega et al. | Jun 2006 | A1 |
20060142812 | Ortega et al. | Jun 2006 | A1 |
20060224197 | Havel et al. | Oct 2006 | A1 |
20060224224 | Muhlenberg et al. | Oct 2006 | A1 |
20070027488 | Kaiser et al. | Feb 2007 | A1 |
20070060961 | Echt et al. | Mar 2007 | A1 |
20070093872 | Chirife et al. | Apr 2007 | A1 |
20070093874 | Chirife et al. | Apr 2007 | A1 |
20070129764 | Burnes | Jun 2007 | A1 |
20070208387 | Mower | Sep 2007 | A1 |
20070232949 | Saksena | Oct 2007 | A1 |
20070233216 | Liu et al. | Oct 2007 | A1 |
20070239219 | Salo et al. | Oct 2007 | A1 |
20080262587 | Flynn et al. | Oct 2008 | A1 |
20080319496 | Zhu et al. | Dec 2008 | A1 |
20080319499 | Zhu et al. | Dec 2008 | A1 |
20080319500 | Zhu et al. | Dec 2008 | A1 |
20080319501 | Zhu et al. | Dec 2008 | A1 |
20090005830 | Zhu et al. | Jan 2009 | A1 |
20090005832 | Zhu et al. | Jan 2009 | A1 |
20090005846 | Zhu et al. | Jan 2009 | A1 |
20090054942 | Zhu et al. | Feb 2009 | A1 |
20090093859 | Ortega et al. | Apr 2009 | A1 |
20090093861 | Ortega et al. | Apr 2009 | A1 |
20090099619 | Lessmeier et al. | Apr 2009 | A1 |
20090105778 | Lee et al. | Apr 2009 | A1 |
20090259272 | Reddy et al. | Oct 2009 | A1 |
20100042176 | Snell | Feb 2010 | A1 |
20100318147 | Forslund et al. | Dec 2010 | A1 |
20110264168 | Dadd et al. | Oct 2011 | A1 |
20110307026 | Zhu et al. | Dec 2011 | A1 |
20110319772 | Ingle | Dec 2011 | A1 |
20110319956 | Zhu et al. | Dec 2011 | A1 |
20120041500 | Zhu et al. | Feb 2012 | A1 |
20120041503 | Zhu et al. | Feb 2012 | A1 |
20120053651 | Zhu et al. | Mar 2012 | A1 |
20120101539 | Zhu et al. | Apr 2012 | A1 |
20120239106 | Maskara et al. | Sep 2012 | A1 |
20130041423 | Zhu et al. | Feb 2013 | A1 |
Number | Date | Country |
---|---|---|
2005319498 | Jul 2011 | AU |
2827595 | Apr 1979 | DE |
3712082 | Oct 1988 | DE |
0042551 | Dec 1981 | EP |
0057877 | Aug 1982 | EP |
0282047 | Sep 1988 | EP |
0321764 | Jun 1989 | EP |
0452278 | Oct 1991 | EP |
0573275 | Dec 1993 | EP |
0591053 | Apr 1994 | EP |
0612538 | Aug 1994 | EP |
0620024 | Oct 1994 | EP |
0672431 | Sep 1995 | EP |
0709111 | May 1996 | EP |
1234597 | Aug 2002 | EP |
2465489 | Mar 1981 | FR |
2575925 | Jul 1986 | FR |
2757773 | Jul 1998 | FR |
2240721 | Aug 1991 | GB |
5501211 | Mar 1993 | JP |
10-052507 | Feb 1998 | JP |
2008539894 | Nov 2008 | JP |
WO-9220401 | Nov 1992 | WO |
WO-9422525 | Oct 1994 | WO |
WO-9615665 | May 1996 | WO |
WO-9740883 | Nov 1997 | WO |
WO-0074773 | Dec 2000 | WO |
WO-03035170 | May 2003 | WO |
WO-2005011475 | Feb 2005 | WO |
WO-2006068880 | Jun 2006 | WO |
WO-2008063498 | May 2008 | WO |
WO-2009006321 | Jan 2009 | WO |
WO-2009006325 | Jan 2009 | WO |
WO-2009006327 | Jan 2009 | WO |
WO-2009006331 | Jan 2009 | WO |
WO-2009006339 | Jan 2009 | WO |
WO-2009078751 | Jun 2009 | WO |
WO-2010042910 | Apr 2010 | WO |
WO-2010071849 | Jun 2010 | WO |
WO-2011139691 | Nov 2011 | WO |
WO-2012005985 | Jan 2012 | WO |
WO-2012125273 | Sep 2012 | WO |
WO-2012125273 | Sep 2012 | WO |
Entry |
---|
US 6,875,206, 04/2005, Ponzi (withdrawn) |
“U.S. Appl. No. 10/004,695, Non-Final Office Action mailed Dec. 22, 2003”, 6 pgs. |
“U.S. Appl. No. 10/004,695, Notice of Allowance mailed Apr. 13, 2004”, 7 pgs. |
“U.S. Appl. No. 10/004,695, Response filed Mar. 9, 2004 to Non-Final Office Action mailed Dec. 22, 2003”, 8 pgs. |
“U.S. Appl. No. 10/745,302, Non-Final Office Action mailed Mar. 14, 2006”, 19 pgs. |
“U.S. Appl. No. 10/745,302, Non-Final Office Action mailed Sep. 14, 2006”, 14 pgs. |
“U.S. Appl. No. 10/745,302, Non-Final Office Action mailed Sep. 23, 2005”, 11 pgs. |
“U.S. Appl. No. 10/745,302, Notice of Allowance mailed Mar. 12, 2007”, 4 pgs. |
“U.S. Appl. No. 10/745,302, Response filed Jun. 26, 2006 to Non Final Office Action mailed Mar. 14, 2006”, 16 pgs. |
“U.S. Appl. No. 10/745,302, Response filed Sep. 12, 2005 to Restriction Requirement mailed Aug. 12, 2005”, 6 pgs. |
“U.S. Appl. No. 10/745,302, Response filed Dec. 14, 2006 to Non Final Office Action mailed Sep. 14, 2006”, 13 pgs. |
“U.S. Appl. No. 10/745,302, Response filed Dec. 23, 2005 to Non Final Office Action mailed Sep. 23, 2005”, 15 pgs. |
“U.S. Appl. No. 10/745,302, Restriction Requirement mailed Aug. 12, 2005”, 7 pgs. |
“U.S. Appl. No. 11/300,242, Final Office Action mailed Aug. 4, 2009”, 9 pgs. |
“U.S. Appl. No. 11/300,242, Non Final Office Action mailed May 12, 2011”, 9 pgs. |
“U.S. Appl. No. 11/300,242, Non-Final Office Action mailed Mar. 27, 2008”, 8 pgs. |
“U.S. Appl. No. 11/300,242, Notice of Allowance mailed Jan. 24, 2012”, 5 pgs. |
“U.S. Appl. No. 11/300,242, Notice of Allowance mailed Mar. 8, 2012”, 6 pgs. |
“U.S. Appl. No. 11/300,242, Notice of Allowance mailed Aug. 24, 2012”, 7 pgs. |
“U.S. Appl. No. 11/300,242, Response filed Feb. 4, 2010 to Final Office Action mailed Aug. 4, 2009”, 11 pgs. |
“U.S. Appl. No. 11/300,242, Response filed Apr. 2, 2009 to Restriction Raquirement mailed Dec. 15, 2008”, 8 pgs. |
“U.S. Appl. No. 11/300,242, Response filed Sep. 12, 2011 to Non Final Office Action mailed May 12, 2011”, 8 pgs. |
“U.S. Appl. No. 11/300,242, Response filed Sep. 26, 2008 to Non-Final Office Action mailed Mar. 27, 2008”, 10 pgs. |
“U.S. Appl. No. 11/300,242, Restriction Requirement mailed Dec. 15, 2008”, 10 pgs. |
“U.S. Appl. No. 11/300,611, 312 Amendment filed Feb. 9, 2009”, 9 pgs. |
“U.S. Appl. No. 11/300,611, Non-Final Office Action mailed Mar. 20, 2008”, 7 pgs. |
“U.S. Appl. No. 11/300,611, Notice of Allowance mailed Jan. 26, 2009”, 7 pgs. |
“U.S. Appl. No. 11/300,611, PTO Response to 312 Amendment mailed Feb. 26, 2009”, 3 pgs. |
“U.S. Appl. No. 11/300,611, Response filed Sep. 22, 2008 to Non-Final Office Action mailed Mar. 20, 2008”, 12 pgs. |
“U.S. Appl. No. 12/147,292, Notice of Allowance mailed Apr. 8, 2011”, 12 pgs. |
“U.S. Appl. No. 12/147,293, Response filed Feb. 8, 2011 to Restriction Requirement mailed Oct. 8, 2010”, 9 pgs. |
“U.S. Appl. No. 12/147,293, Restriction Requirement mailed Oct. 8, 2010”, 12 pgs. |
“U.S. Appl. No. 12/147,317 , Response filed Apr. 11, 2012 to Final Office Action mailed Oct. 12, 2011”, 8 pgs. |
“U.S. Appl. No. 12/147,317, Examiner Interview Summary mailed Mar. 15, 2011”, 3 pgs. |
“U.S. Appl. No. 12/147,317, Final Office Action mailed Oct. 12, 2011”, 6 pgs. |
“U.S. Appl. No. 12/147,317, Non-Final Office Action mailed Dec. 28, 2010”, 7 pgs. |
“U.S. Appl. No. 12/147,317, Notice of Allowance mailed Jul. 2, 2012”, 7 pgs. |
“U.S. Appl. No. 12/147,317, Response filed Jun. 27, 2011 to Non Final Office Action mailed Dec. 28, 2010”, 11 pgs. |
“U.S. Appl. No. 12/147,339, Notice of Allowance mailed Mar. 30, 2011”, 9 pgs. |
“U.S. Appl. No. 12/147,339, Notice of Allowance mailed Dec. 22, 2010”, 8 pgs. |
“U.S. Appl. No. 12/147,339, Response filed Oct. 20, 2010 to Restriction Requirement mailed Oct. 8, 2010”, 7 pgs. |
“U.S. Appl. No. 12/147,339, Restriction Requirement mailed Oct. 8, 2010”, 7 pgs. |
“U.S. Appl. No. 12/147,356, Notice of Allowance mailed Feb. 10, 2011”, 17 pgs. |
“U.S. Appl. No. 12/147,356, Notice of Allowance mailed Jun. 30, 2011”, 15 pgs. |
“U.S. Appl. No. 12/147,356, Response filed Nov. 10, 2010 to Restriction Requirement mailed Oct. 12, 2010”, 9 pgs. |
“U.S. Appl. No. 12/147,356, Restriction Requirement mailed Oct. 12, 2010”, 7 pgs. |
“U.S. Appl. No. 12/147,369, Non-Final Office Action mailed Sep. 10, 2010”, 10 pgs. |
“U.S. Appl. No. 12/147,369, Notice of Allowance mailed Apr. 21, 2011”, 7 pgs. |
“U.S. Appl. No. 12/147,369, Response filed Feb. 10, 2011 to Non Final Office Action mailed Sep. 10, 2010”, 7 pgs. |
“U.S. Appl. No. 12/147,376 , Response filed Feb. 29, 2012 to Non Final Office Action mailed Oct. 3, 2011”, 6 pgs. |
“U.S. Appl. No. 12/147,376, Final Office Action mailed Apr. 20, 2011”, 11 pgs. |
“U.S. Appl. No. 12/147,376, Non Final Office Action mailed Oct. 3, 2011”, 8 pgs. |
“U.S. Appl. No. 12/147,376, Non-Final Office Action mailed Sep. 15, 2010”, 9 pgs. |
“U.S. Appl. No. 12/147,376, Notice of Allowance mailed Mar. 19, 2012”, 7 pgs. |
“U.S. Appl. No. 12/147,376, Notice of Allowance mailed Aug. 30, 2012”, 7 pgs. |
“U.S. Appl. No. 12/147,376, Response filed Feb. 15, 2011 to Non Final Office Action mailed Sep. 15, 2010”, 9 pgs. |
“U.S. Appl. No. 12/147,376, Response filed Aug. 22, 2011 to Final Office Action mailed Apr. 20, 2011”, 8 pgs. |
“U.S. Appl. No. 12/147,425, Non-Final Office Action mailed Sep. 15, 2010”, 10 pgs. |
“U.S. Appl. No. 12/147,425, Notice of Allowance mailed Apr. 19, 2011”, 8 pgs. |
“U.S. Appl. No. 12/147,425, Response filed Feb. 15, 2011 to Non Final Office Action mailed Sep. 15, 2010”, 8 pgs. |
“U.S. Appl. No. 12/249,454, Examiner Interview Summary mailed Feb. 22, 2012”, 3 pgs. |
“U.S. Appl. No. 12/249,454, Final Office Action mailed Nov. 23, 2011”, 8 pgs. |
“U.S. Appl. No. 12/249,454, Non Final Office Action mailed Apr. 6, 2011”, 8 pgs. |
“U.S. Appl. No. 12/249,454, Non Final Office Action mailed Sep. 4, 2012”, 8 pgs. |
“U.S. Appl. No. 12/249,454, Response filed Apr. 2, 2012 to Final Office Action mailed Nov. 23, 2011”, 12 pgs. |
“U.S. Appl. No. 12/249,454, Response filed Aug. 30, 2011 to Non Final Office Action mailed Apr. 6, 2011”, 14 pgs. |
“U.S. Appl. No. 12/249,479, Final Office Action mailed Dec. 2, 2011”, 8 pgs. |
“U.S. Appl. No. 12/249,479, Non Final Office Action mailed Apr. 5, 2011”, 10 pgs. |
“U.S. Appl. No. 12/249,479, Non Final Office Action mailed Sep. 4, 2012”, 7 pgs. |
“U.S. Appl. No. 12/249,479, Response filed Apr. 2, 2012 to Final Office Action mailed Dec. 2, 2011”, 9 pgs. |
“U.S. Appl. No. 12/249,479, Response filed Aug. 30, 2011 to Non Final Office Action mailed Apr. 5, 2011”, 12 pgs. |
“U.S. Appl. No. 12/249,508, Notice of Allowance mailed Feb. 14, 2012”, 7 pgs. |
“U.S. Appl. No. 12/249,508, Notice of Allowance mailed Jun. 12, 2012”, 7 pgs. |
“U.S. Appl. No. 12/249,508, Notice of Allowance mailed Oct. 5, 2011”, 9 pgs. |
“U.S. Appl. No. 12/249,508, Response filed Aug. 30, 2011 to Restriction Requirement mailed Jun. 30, 2011”, 8 pgs. |
“U.S. Appl. No. 12/249,508, Restriction Requirement mailed Jun. 30, 2011”, 6 pgs. |
“U.S. Appl. No. 12/412,608, Final Office Action mailed Nov. 21, 2011”, 6 pgs. |
“U.S. Appl. No. 12/412,608, Non Final Office Action mailed May 26, 2011”, 8 pgs. |
“U.S. Appl. No. 12/412,608, Notice of Allowance mailed Jun. 6, 2012”, 7 pgs. |
“U.S. Appl. No. 12/412,608, Response filed Apr. 18, 2012 to Final Office Action mailed Nov. 21, 2011”, 7 pgs. |
“U.S. Appl. No. 12/412,608, Response filed Sep. 26, 2011 to Non Final Office Action mailed May 26, 2011”, 9 pgs. |
“ATROSTIM Phrenic Nerve Stimulator”, Product Brochure, AtroTech Oy, P.O. Box 28, FIN-33721 Tampere, Finland, (Jun. 2004), 2 pgs. |
“Australian Application Serial No. 2005319498, First Examiner Report mailed May 27, 2010”, 3 pgs. |
“Australian Application Serial No. 2005319498, Response filed Feb. 21, 2011 to First Examiner Report mailed May 27, 2010”, 11 pgs. |
“Coating Process for Composite Implants”, Medical Materials Update, vol. 1, No. 12, (Jan. 1995), 3 pgs. |
“European Application Serial No. 05849548.2, Communication and Supplementary Partial European Search Report mailed Feb. 29, 2008”, 8 pgs. |
“European Application Serial No. 05849548.2, Communication mailed Jun. 9, 2009”, 3 pgs. |
“European Application Serial No. 05849548.2, Office Action mailed Dec. 20, 2010”, 4 pgs. |
“European Application Serial No. 05849548.2, Response filed Jun. 29, 2011 to Non Final Office Action mailed Dec. 20, 2010”, 9 pgs. |
“European Application Serial No. 05849548.2, Response filed Dec. 16, 2009 to Communication mailed Jun. 9, 2009”, 10 pgs. |
“European Application Serial No. 08772198.1, Office Action mailed Sep. 13, 2010”, 6 pgs. |
“European Application Serial No. 08772198.1, Response filed Mar. 31, 2011 to Communication mailed Sep. 30, 2010”, 11 pgs. |
“European Application Serial No. 08781107.1, Invitation Pursuant to Rule 63(1) EPC mailed Jul. 13, 2010”, 3 pgs. |
“European Application Serial No. 08781107.1, Communication dated Feb. 9, 2010”, 2 pgs. |
“European Application Serial No. 08781107.1, Extended European Search Report mailed Nov. 25, 2010”, 6 pgs. |
“European Application Serial No. 08781107.1, Response filed Mar. 5, 2010 to Communication dated Feb. 9, 2010”, 2 pgs. |
“European Application Serial No. 08781107.1, Response filed Jun. 14, 2011 to Communication mailed Dec. 14, 2010”, 10 pgs. |
“European Application Serial No. 08781107.1, Response filed Sep. 22, 2010 to the Invitation to Rule 63(1)”, 11 pgs. |
“European Application Serial No. 08796045.6, European Search Report mailed Sep. 21, 2010”, 6 pgs. |
“European Application Serial No. 08796045.6, Office Action mailed Jan. 4, 2012”, 4 pgs. |
“European Application Serial No. 08796045.6, Response filed Apr. 15, 2011 to Communication dated Oct. 8, 2010”, 10 pgs. |
“European Application Serial No. 08796045.6, Response filed May 14, 2012 to Office Action mailed Jan. 4, 2012”, 8 pgs. |
“Implant Attaches to Bone by Chemical Bond”, Medical Materials Update, vol. 4, No. 7, (Aug. 1997), 2 pgs. |
“International Application Serial No. PCT/US05/45044, International Search Report mailed May 2, 2006”, 1 pg. |
“International Application Serial No. PCT/US05/45044, Written Opinion mailed May 2, 2006”, 3 pgs. |
“International Application Serial No. PCT/US08/68618, International Search Report mailed Nov. 26, 2008”, 2 pgs. |
“International Application Serial No. PCT/US08/68618, Written Opinion mailed Nov. 26, 2008”, 6 pgs. |
“International Application Serial No. PCT/US08/68627, International Search Report mailed Sep. 10, 2008”, 1 pg. |
“International Application Serial No. PCT/US08/68627, Written Opinion maiied Sep. 10, 2008”, 4 pgs. |
“International Application Serial No. PCT/US08/68630, International Search Report mailed Sep. 10, 2008”, 1 pg. |
“International Application Serial No. PCT/US08/68630, Written Opinion mailed Sep. 10, 2008”, 4 pgs. |
“International Application Serial No. PCT/US08/68632, International Search Report mailed Sep. 11, 2008”, 2 pgs. |
“International Application Serial No. PCT/US08/68632, Written Opinion mailed Sep. 11, 2008”, 4 pgs. |
“International Application Serial No. PCT/US08/68647, International Search Report mailed Sep. 22, 2008”, 2 pgs. |
“International Application Serial No. PCT/US08/68647, Written Opinion mailed Sep. 22, 2008”, 4 pgs. |
“International Application Serial No. PCT/US08/68654, International Search Report mailed Sep. 22, 2008”, 2 pgs. |
“International Application Serial No. PCT/US08/68654, Written Opinion mailed Sep. 22, 2008”, 4 pgs. |
“International Application Serial No. PCT/US2008/068635, International Search Report mailed Sep. 9, 2008”, 3 pgs. |
“International Application Serial No. PCT/US2008/068635, Written Opinion mailed Sep. 9, 2008”, 4 pgs. |
“International Application Serial No. PCT/US2009/060293, International Preliminary Report on Patentability mailed Apr. 12, 2011”, 10 pgs. |
“International Application Serial No. PCT/US2009/060293, International Search Report mailed Mar. 10, 2010”, 6 pgs. |
“International Application Serial No. PCT/US2009/060293, Invitation to Pay Additional Fee mailed Dec. 18, 2009”, 5 pgs. |
“International Application Serial No. PCT/US2009/060293, Written Opinion mailed Mar. 10, 2010”, 10 pgs. |
“International Application Serial No. PCT/US2009/068859, International Search Report mailed Jul. 5, 2010”, 7 pgs. |
“International Application Serial No. PCT/US2009/068859, Invitation to Pay Additional Fee mailed Apr. 15, 2010”, 6 pgs. |
“International Application Serial No. PCT/US2009/068859, Written Opinion mailed Jul. 5, 2010”, 12 pgs. |
“International Application Serial No. PCT/US2011/033944, International Search Report mailed Sep. 8, 2011”, 5 pgs. |
“International Application Serial No. PCT/US2011/033944, Written Opinion mailed Sep. 8, 2011”, 9 pgs. |
“Japanese Application Serial No. 2007-548289, Final Office Action dated Aug. 2, 2011”, (w/ English Translation), 5 pgs. |
“Japanese Application Serial No. 2007-548289, Office Action mailed Mar. 6, 2012”, (w/ English Translation), 3 pgs. |
“Japanese Application Serial No. 2007-548289, Office Action mailed Nov. 24, 2010”, (w/ English Translation), 7 pgs. |
“Japanese Application Serial No. 2007-548289, Response filed May 20, 2011 to Office Action mailed Nov. 24, 2010”, (w/ English Translation of Amended Claims), 9 pgs. |
“Japanese Application Serial No. 2007-548289, Response filed Jun. 4, 2012 to Office Action mailed Mar. 6, 2012”, 3 pgs. |
“Japanese Application Serial No. 2007-548289, Response filed Oct. 26, 2011 to Office Action mailed Aug. 3, 2011”, (w/ English Translation of Amended Claims), 10 pgs. |
“Victrex's PEEK Used for Dialysis Machines”, Medical Material's Update, vol. 3, No. 3, (Apr. 1996), pp. 1-2. |
Alboni, P., “Bundle Branch Blocks Anatomically Located in the His Bundle”, Italian Cardiology Journal, 10(12), (w/ English Translation thereof, followed by Italian publication), (1980), 1583-1587. |
Al-Khadra, A., et al., “The Role of Electroporation in Defibrillation”, Circulation Research, 87(9), (Oct. 2000), 797-804. |
Arcot-Krishnamurthy, S., et al., “Timing for His-Bundle Pacing”, U.S. Appl. No. 13/277,617, filed Oct. 20, 2011, 40 pgs. |
Avitall, B., et al., “Iontophoretic Transmyocardial Drug Delivery. A Novel Approach to Antiarrhythmic Drug Therapy”, Circulation, 85(4), (1992), 1582-1593. |
Barba-Pichardo, Rafael, et al., “Permanent His-Bundle Pacing in Patients With Infra-Hisian Atrioventricular Block”, Rev Esp Cardiol. 59(6), (Mar. 9, 2006), 553-558. |
Barton, A. J., et al., “Bacterial Adhesion to Orthopedic Implant Polymers”, J. Biomed. Mat. Res., 30(3), (Mar. 1996), 403-410. |
Bonanno, C., et al., “Effect on QRS Duration and Feasibility of Septal and Multisite Right Ventricular Pacing”, Cardiostimolazione, 14(3), (Abstract Only), (Sep. 1996), p. 195. |
Buckingham, Thomas A., et al., “Acute Hemodynamic Effects of Atrioventricular Pacing at Differing Sites in the Right Ventricle Individually and Simultaneously”, PACE, 20[Pt. I], (Apr. 1997), 909-915. |
Cantu, F., et al., “Validation of Criteria for Selective His Bundie and Para-Hisian Permanent Pacing”, PACE, vol. 29, (Dec. 2006), 1326-1333. |
Cantu, Francesco, et al., “A Methodical Approach to Validate Selective His Bundle and para-Hisian Permanent Pacing”, [abstract] Oasis, (2006), 1 pg. |
Catanzariti, Domenico, et al., “Permanent His Bundle Pacing Does Not Induce Ventricular Dyssynchrony. An Echocardiographic Intrapatient Study of Comparison with Conventional Pacing”, [abstract] Oasis, (2006), 1 pg. |
Chiu, L., et al., “Method for One-Click Deployment and or Configuration of Real-Time Software System Modifications”, U.S. Appl. No. 60/558,921, filed Apr. 2, 2004, 8 pgs. |
Chudzik, Michal, “Ventricular Endocardial Right Bifocal Stimulation in Treatment of Severe Dilated Cardiomyopathy Heart Failure in Patients with Unsuccessful Biventricular Pacemaker Impiantation”, [abstract CP07] Europace Supplements, vol. 7, (May 2005), 1 pg. |
Deshmukh, P., et al., “Permanent, Direct His-Bundle Pacing: A Novel Approach to Cardiac Pacing in Patients With Normal His-Purkinje Activation”, Circulation, 101(8), (Feb. 29, 2000), 869-877. |
Deshmukh, Pramod M., et al., “Direct His-Bundle Pacing: Present and Future”, PACE, vol. 27, Part II, (Jun. 2004), 862-870. |
Dong, Y., et al., “His-Bundle Capture Verification and Monitoring”, U.S. Appl. No. 61/328,248, filed Apr. 27, 2010, 40 pgs. |
El-Sherif, N., et al., “Normalization of Bundle Branch Block Patterns by Distal His Bundle Pacing: Clinical and Experimental Evidence of Longitudinal Dissociation in the Pathologic His Bundle”, Circulation, 57(3), (Mar. 1978), 473-483. |
Flynn, David M, et al., “Extendable and Retractable Lead Having a Snap-Fit Terminal Connector”, U.S. Appl. No. 11/173,664, filed Jul. 1, 2005, 53 pgs. |
Furman, S., et al., “Chapter 5—Permanent Pacemaker Implementation”, A Practice of Cardiac Pacing, Futura Publishing Co., Inc. Mount Kisco, NY, (1986), 97-127. |
Genc, S., et al., “Methodology for Locking Feature Selection in Integral Snap-Fit Assembly”, Proceedings of DETC '97, 1997 ASME Engineering Technical Conferences, (Sep. 1997), 1-11. |
Golia, P., et al., “Multisite Pacing of Right Ventricle in Heart Failure: Echocardiographic Evaluation”, [Abstract] Cardiostimolazione, vol. 14, No. 3, (Sep. 1996), 5 pgs. |
Grosfeld, M. J.W., et al., “Testing a New Mechanism for Left Interventricular Septal Pacing: The Transseptal Route”, Europace, vol. 4, (Oct. 2002), 439-444. |
Ha, S. W., et al., “Plasma-Sprayed Hydroxylapatite Coating on Carbon Fibre Reinforced Thermoplastic Composite Materials”, J. Mater. Sci. Mater. Med., vol. 5, No. 6-7, (1994), pp. 481-484. |
Hummel, J. D., et al., “Augmentation of Cardiac Output by Anodal Pacing”, [Abstract] Circulation, 90(No. 4, Part 2), (Oct. 1994), p. I-69. |
Ingle, Frank, et al., “Lead Motion Sensing Via Cable Microphonics”, U.S. Appl. No. 61/359,430, filed Jun. 29, 2010, 52 pgs. |
Jockisch, K. A., et al., “Biological Response to Chopped-Carbon-Fiber-Reinforced Peek”, J. Biomed. Mater. Res., vol. 26, No. 2, (1992), pp. 133-146. |
Kanno, S., et al., “Establishment of a simple and practical procedure applicable to therapeutic angiogenesis”, Circulation, 99(20), (May 25, 1999), 2682-2687. |
Kavanagh, K. M., et al., “Monophasic Versus Biphasic Cardiac Stimulation: Mechanism of Decreased Energy Requirements”, PACE, vol. 13, No. 10, (Oct. 1990), 10 pgs. |
Kaye, D. M., et al., “Frequency-dependent activation of a constitutive nitric oxide synthase and regulation of contractile function in adult rat ventricular myocytes”, Circulation Research, 78(2), (Feb. 1996), 217-24. |
Knapp, C. P. et al., “Snap Fit Terminal Connector”, U.S. Appl. No. 09/184,226, filed Nov. 2, 1998, 39 pgs. |
Kutarski, A., et al., “Factors Influencing Differences of RVA & RVOT Pacing Hemodynamic Effects”, [abstract CP05] Europace Supplements, vol. 7, (May 2005), p. 288. |
Kutarski, A., et al., “Right Ventricular Outflow Tract and Dual Site Right Ventricular Pacing—The Comparison With Apex Pacing”, [abstract CP08] Europace Supplements, vol. 7, (May 2005), p. 288. |
Labhasetwar, V., et al., “Iontophoresis for Modulation of Cardiac Drug Delivery in Dogs”, Proc. Natl. Acad.Sci. USA, 92(7), (Mar. 28, 1995), 2612-2616. |
Lazarus, A., et al., “Reduction in Energy Pacing Thresholds by Overlapping Biphasic Stimulation Versus Conventional Bipolar Pacing”, PACE, vol. 21, (Nov. 1998), 6 pgs. |
Lin, T. W., et al., “Glass Peek Composite Promotes Proliferation and Osteocalcin of Human Osteoblastic Cells”, J. Biomed. Mater. Res., vol. 36, No. 2, (1997), pp. 137-144. |
Lupi, G., et al., “Effects of Right Ventricular Pacing on Intra-Left Ventricular Electromechanical Activation in Patients with Native Narrow QRS.”, American Journal of Cardiology, vol. 98, (2006), 219-222. |
MacNair, R., et al., “The Response of Primary Rat and Human Osteoblasts and an Immortalized Rat Osteoblast Cell Line to Orthopaedic Materials: Comparative Sensitivity of Several Toxicity Indices”, J. Mater. Sci. Mater. Med., vol. 8, No. 2, (1997), pp. 105-111. |
Manolis, Antonis S., “The Deleterious Consequences of Right Ventricular Apical Pacing: Time to Seek Alternate Site Pacing”, PACE, vol. 29, (Mar. 2006), 298-315. |
Mansourati, J., et al., “Left ventricular-based pacing in patients with chronic heart failure: comparison of acute hemodynamic benefits according to underlying heart disease”, Eur J Heart Fail., 2 2), (Jun. 2000), 195-9. |
Meyer, M. R., et al., “Long-Term Durability of the Interface in FRP Composites After Exposure to Simulated Physiologic Saline Environments”, J. Biomed. Mater. Res., 28(10), (1994), 1221-1231. |
Mond, Harry G., et al., “The Right Ventricular Outflow Tract: The Road to Septal Pacing”, PACE, vol. 30, (Apr. 2007), 482-491. |
Morina-Vazquez, Pablo, et al., “Cardiac Resynchronization Through Selective His Bundle Pacing in a Patient with the So-Called InfraHis Atrioventricular Block”, PACE, vol. 28, (Jul. 2005), 726-729. |
Morrison, C., et al., “In Vitro Biocompatibility Testing of Polymers for Orthopaedic Implants Using Cultured Fibroblasts and Osteoblasts”, Biomaterials, vol. 16, No. 13, (1995), pp. 987-992. |
Narula, O. S., “Longitudinal Dissociation in the His Bundle. Bundle Branch Block Due to Asynchronous Conduction Within the His Bundle in Man”, Circulation, 56(6), (Dec. 1977), 996-1006. |
Occhetta, E., et al., “Prevention of Ventricular Desynchronization by Permanent Para-Hisian Pacing After Atrioventricular Node Ablation in Chronic Atrial Fibrillation: A Crossover, Blinded, Randomized Study Versus Apical Right Ventricular Pacing”, Journal of the American College of Cardiology, 47(10), (May 16, 2006), 1938-1945. |
Padeletti, Luigi, et al., “Physiologic Pacing: New Modalities and Pacing Sites”, PACE, vol. 29, Supplement 2, (Dec. 2006), S73-S77. |
Pastore, G., et al., “Different Degree of Ventricular Dyssyncrony Induced by Right Apical, Hissian and Para Hissian Ventricular Pacing”, [abstract] Oasis, (2006), 1 pg. |
Pastore, Gianni, et al., “Direct His-Bundle Pacing Preserves the Normal Left Activation Sequence: An Acute Echocardiographic Study”, [abstract] Oasis, (2006), 1 pg. |
Puech, P., et al., “Narrowing and normalization of QRS stimulation of the His bundle in complete left bundle branch block.”, Scholarly Journal of the French Cardiology Society, vol. 72, No. 8, (w/ English Translation thereof, followed by French publication), (Aug. 1979), 815-824. |
Qu, J, et al., “HCN2 overexpression in newborn and adult ventricular myocytes: distinct effects on gating and excitability”, Circ. Res., vol. 89(1), (Jul. 6, 2001), e8-14. |
Qu, J, et al., “Sympathetic innervation alters activations of pacemaker current (If) in rat ventricle”, J. Physiol, 526 Pt 3, (Aug. 1, 2000), 561-569. |
Ravazzi, A., et al., “Improvement of Interventricular Activation Time Using Biphasic Pacing Pulses at Different Sites on Right Ventricle Septal Wall”, Progress in Biomedical Research, 4(3), (Jun. 1999), 248-253. |
Reddy, G. S., “Bundle of His Stimulation System”, U.S. Appl. No. 61/045,168, filed Apr. 15, 2008, 37 pgs. |
Saksena, S., et al., “Chapter 9—Pacemaker Implantation Techniques”, Electrical Therapy for Cardiac Arrhythmias, W.B. Saunders Co., Philadelphia, PA, (1990), pp. 173, 181-183. |
Scheinman, M. M., et al., “Long-Term His-Bundie Pacing and Cardiac Function”, Circulation, 101(8), (2000), 836-837. |
Schoenfeld, M. H., “Alternative Site Pacing to Promote Cardiac Synchrony: Has Conventional Pacing Become Unconventional?”, Journal of the American College of Cardiology, 47(10), (2006), 1946-1948. |
Shi, W, et al., “Distribution and prevalence of hyperpolarization-activated cation channel (HCN) mRNA expression in cardiac tissues”, Circ. Res., vol. 85(1), (Jul. 9, 1999), e1-6. |
Sotobata, I., et al., “Population distribution of Frank-vectorcardiographic measurements of healthy Japanese men”, Japanese Circulation Journal, 39(8), (1975), 895-903. |
Soyer, J., et al., “Experimental Characterisation of a Carbon/PEEK Hip Prothesis in Fatigue”, Chirurgie, 121, (1996), p. 658-663. |
Sweeney, M. O., et al., “Adverse Effect of Ventricular Pacing on Heart Failure and Atrial Fibrillation Among Patients with Normal Baseline QRS Duration in a Clinical Trial of Pacemaker Therapy for Sinus Node Dysfunction”, Circulation, 107(23), (2003), 2932-2937. |
Sweeney, M. O., et al., “Heart Failure During Cardiac Pacing”, Circulation, 113(17), (2006), 2082-2088. |
Takatsuki, et al., “Clinical Implications of “pure” Hisian pacing in addition to para-Hisian pacing for the diagnosis of supraventricular tachycardia”, Heart Rhythm 3 (12), (Dec. 8, 2006), 1412-1418. |
Tanabe, M., et al., “Biventricular Pacing Worsened Dyssynchrony in Heart Failure Patient with Right-Bundle Branch Block”, International Journal of Cardiology, 138(3), (available online Aug. 15, 2008 / epub doi:10.1016/j.ijcard.2008.06.063 ), (2010), e47-e50. |
Thakral, A, et al., “Effects of anodal vs. cathodal pacing on the mechanical performance of the isolated rabbit heart”, J. Appl Physiol., 89(3), (Sep. 2000), 1159-64. |
Tse, Hung-Fat, et al., “Selection of Permanent Ventricular Pacing Site: How Far Should We Go?”, Journal of the American College of Cardiology, 48(8), (Sep. 26, 2006), 1649-1651. |
Van Gelder, B. M., et al., “Hemodynamic Effect of RV Apex vs RV Septum Pacing in a Monoventricular and Biventricuiar Configuration in Patients with Heart Failure”, [abstract CP06] Europace Supplements, vol. 7, (May 2005), p. 288. |
Victor, F., et al., “A Randomized Comparison of Permanent Septal Versus Apical Right Ventricular Pacing: Short-Term Results”, Journal of Cardiovascular Electrophysiology, 17(3), (Mar. 2006), 238-242. |
Wang, S. C.-J., et al., “Improved Method and System for Managing Voice Prompt Recordings Prior to Deployment”, U.S. Appl. No. 60/532,271, filed Dec. 23, 2003, 12 pgs. |
Wenz, L. M., et al., “In Vitro Biocompatibility of Polyetheretherketone and Polysulfone Composites”, J. Biomed. Mater. Res., vol. 26, No. 2, (1990), pp. 207-215. |
Winckels, S. K. G., et al., “High-Septal Pacing Reduces Ventricular Electrical Remodeling and Proarrhythmia in Chronic Atrioventricular Block Dogs”, Journal of the American College of Cardiology, 50(9), (Aug. 28, 2007), 906-913. |
Yu, H., et al., “MinK-related peptide 1: A beta subunit for the HCN ion channel subunit family enhances expression and speeds activation”, Circ. Res., 88(12), (Jun. 22, 2001), e84-7. |
Zanon, F., et al., “A Feasible Approach for Direct His-Bundle Pacing Using a New Steerable Catheter to Facilitate Precise Lead Placement”, Journal of Cardiovascular Electrophysiology, 17(1), (Jan. 2006), 29-33. |
Zanon, Francesco, et al., “A New Technique for Direct His-Bundle Pacing: Acute and Mid-Term Electrical Data Results”, [abstract] Oasis, (2006), 1 pg. |
Zanon, Francesco, et al., “Direct His Bundle Pacing Preserves Coronary Perfusion Compared With Right Ventricular Apical Pacing: A Prospective, Cross-Over Mid-Term Study”, Europace, vol. 10, (2008), 580-587. |
Zhang, Y., et al., “His Electrogram Alternans Reveal Dual-Wavefront Inputs Into and Longitudinal Dissociation Within the Bundle of His”, Circulation,104(7), (2001), 832-838. |
Zhu, Q., et al., “Methods, Devices and Systems for Cardiac Pacing Therapies Using Intrinsic Activity”, U.S. Appl. No. 61/139,117, filed Dec. 19, 2008, 22 pgs. |
“U.S. Appl. No. 12/147,376, Notice of Allowance mailed Dec. 7, 2012”, 7 pgs. |
“U.S. Appl. No. 12/249,454, Notice of Allowance mailed Dec. 26, 2012”, 5 pgs. |
“U.S. Appl. No. 12/249,454, Response filed Dec. 4, 2012 to Non Final Office Action mailed Sep. 4, 2012”, 12 pgs. |
“U.S. Appl. No. 12/249,479, Notice of Allowance mailed Jan. 8, 2013”, 5 pgs. |
“U.S. Appl. No. 12/249,479, Response filed Dec. 4, 2012 to Non Final Office Action mailed Sep. 4, 2012”, 9 pgs. |
“U.S. Appl. No. 13/211,937, Non Final Office Action mailed Jan. 15, 2013”, 7 pgs. |
“U.S. Appl. No. 13/217,776, Non Final Office Action mailed Jan. 15, 2013”, 6 pgs. |
“European Application Serial No. 05849548.2, Office Action mailed Jan. 16, 2013”, 3 pgs. |
“International Application Serial No. PCT/US2011/033944, International Preliminary Report on Patentability mailed Nov. 8, 2012”, 9 pgs. |
“International Application Serial No. PCT/US2012/026571, International Search Report mailed Oct. 18, 2012”, 4 pgs. |
“International Application Serial No. PCT/US2012/026571, Written Opinion mailed Oct. 18, 2012”, 7 pgs. |
“Japanese Application Serial No. 2007-548289, Office Action mailed Nov. 6, 2012”, With English Translation, 3 pgs. |
“Japanese Application Serial No. 2007-548289, Response filed Feb. 4, 2013 to Office Action mailed Nov. 6, 2012”, With English Claims, 7 pgs. |
“Japanese Application Serial No. 2010-515189, Office Action mailed Feb. 12, 2013”, With English Translation, 9 pgs. |
“Japanese Application Serial No. 2010-515196, Office Action mailed Jan. 15, 2013”, With English Translation, 8 pgs. |
“Japanese Application Serial No. 2010-515198, Office Action mailed Feb. 12, 2013”, With English Translation, 16 pgs. |
“Japanese Application Serial No. 2011-531237, Office Action mailed Jan. 15, 2013”, With English Translation, 7 pgs. |
“Japanese Application Serial No. 2011-542513, Office Action mailed Jan. 15, 2013”, With English translation, 6 pgs. |
Number | Date | Country | |
---|---|---|---|
20110264158 A1 | Oct 2011 | US |
Number | Date | Country | |
---|---|---|---|
61328248 | Apr 2010 | US |